Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
106.70
(
0.00%
)
Bitcoin
77,918.00
(
-1.44%
)
News Focus
News Focus
Post# of 19309
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Monday, 08/13/2007 7:14:47 AM

Monday, August 13, 2007 7:14:47 AM

Post# of 19309
How is Novo Nordisk preparing for NovoSeven patent expiration?

NVO’s blockbuster rFVIIa drug, NovoSeven, goes off-patent in the US—its largest market—in 2011. NVO has a two-pronged approach to deal with this predicament:

1. A fast-acting FVIIa analogue called NN1731, which is in phase-2:
http://seloken.com/secNewsItem/Variant-rFVIIa-more-active-than-NovoSeven.aspx

2. A long-acting FVIIa analogue called NN7128 based on pegylation technology from NTEC, which is in phase-1 (#msg-21139054).

Clearly, both of these programs warrant close attention by GTC investors. However, these two drug candidates are FVIIa analogues, not FVIIa per se. Thus, they would seem to incur a higher regulatory risk than the FVIIa program from GTC and partner, LFB.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today